Some distinctions between flavin-containing and cytochrome P450 monooxygenases

被引:92
作者
Cashman, JR [1 ]
机构
[1] Human Biomol Res Inst, San Diego, CA 92121 USA
关键词
amine-; sulfide-oxygenation; enzyme mechanism; genetic variation; drug development;
D O I
10.1016/j.bbrc.2005.08.009
中图分类号
Q5 [生物化学]; Q7 [分子生物学];
学科分类号
071010 ; 081704 ;
摘要
This minireview Summarizes information concerning the differences and similarities of the human flavin-containing- (FMO, E.C. 1.14.13.8) and the cytochrome P450-monooxygenases (CYP, E.C. 1.14.14.1). Human FMO oxygenates soft nucleophiles. CYP mainly catalyzes C-H abstraction but also oxidizes nitrogen- and sulfur-containing compounds. Both FMO and CYP generally convert lipophilic compounds into more hydrophilic metabolites. The mechanism by which each monooxygenase operates is quite distinct. Sometimes, CYP or FMO bioactivate chemicals to reactive metabolites but to date, drug toxicity thus far observed in the clinic is mainly, the result of CYP-dependent oxidation. Both FMO and CYP possess genetic variability that may contribute to inter-individual variability observed for drug metabolism. In contrast to CYP, FMO is not induced Or readily inhibited and potential adverse drug-drug interactions are minimized for drugs prominently metabolized by FMO. These properties may provide advantages in drug design, and by incorporating FMO detoxication pathways into drug candidates, more drug-like materials may emerge. (c) 2005 Elsevier Inc. All rights reserved.
引用
收藏
页码:599 / 604
页数:6
相关论文
共 48 条
[1]  
[Anonymous], ENZYMATIC BASIS DETO
[2]  
CASHMAN JR, 1993, DRUG METAB DISPOS, V21, P587
[3]   Human flavin-containing monooxygenase (form 3): polymorphisms and variations in chemical metabolism [J].
Cashman, JR .
PHARMACOGENOMICS, 2002, 3 (03) :325-339
[4]   The implications of polymorphisms in mammalian flavin-containing monoloxygenases in drug discovery and development [J].
Cashman, JR .
DRUG DISCOVERY TODAY, 2004, 9 (13) :574-581
[5]  
Cashman JR, 2003, CURR OPIN DRUG DISC, V6, P486
[6]   Biochemical and clinical aspects of the human flavin-containing monooxygenase form 3 (FMO3) related to trimethylaminuria [J].
Cashman, JR ;
Camp, K ;
Fakharzadeh, SS ;
Fennessey, PV ;
Hines, RN ;
Mamer, OA ;
Mitchell, SC ;
Preti, G ;
Schlenk, D ;
Smith, RL ;
Tjoa, SS ;
Williams, DE ;
Yannicelli, S .
CURRENT DRUG METABOLISM, 2003, 4 (02) :151-170
[7]   STRUCTURAL AND CATALYTIC PROPERTIES OF THE MAMMALIAN FLAVIN-CONTAINING MONOOXYGENASE [J].
CASHMAN, JR .
CHEMICAL RESEARCH IN TOXICOLOGY, 1995, 8 (02) :165-181
[8]   METABOLISM OF NICOTINE BY HUMAN LIVER-MICROSOMES - STEREOSELECTIVE FORMATION OF TRANS-NICOTINE N'-OXIDE [J].
CASHMAN, JR ;
PARK, SB ;
YANG, ZC ;
WRIGHTON, SA ;
JACOB, P ;
BENOWITZ, NL .
CHEMICAL RESEARCH IN TOXICOLOGY, 1992, 5 (05) :639-646
[9]   In vitro and in vivo inhibition of human flavin-containing monooxygenase form 3 (FMO3) in the presence of dietary indoles [J].
Cashman, JR ;
Xiong, Y ;
Lin, J ;
Verhagen, H ;
van Poppel, G ;
van Bladeren, PJ ;
Larsen-Su, S ;
Williams, DE .
BIOCHEMICAL PHARMACOLOGY, 1999, 58 (06) :1047-1055
[10]   Stereoselectivity in S- and N-oxygenation by the mammalian flavin-containing and cytochrome P-450 monooxygenases [J].
Cashman, JR .
DRUG METABOLISM REVIEWS, 1998, 30 (04) :675-707